<code id='95A327F2C2'></code><style id='95A327F2C2'></style>
    • <acronym id='95A327F2C2'></acronym>
      <center id='95A327F2C2'><center id='95A327F2C2'><tfoot id='95A327F2C2'></tfoot></center><abbr id='95A327F2C2'><dir id='95A327F2C2'><tfoot id='95A327F2C2'></tfoot><noframes id='95A327F2C2'>

    • <optgroup id='95A327F2C2'><strike id='95A327F2C2'><sup id='95A327F2C2'></sup></strike><code id='95A327F2C2'></code></optgroup>
        1. <b id='95A327F2C2'><label id='95A327F2C2'><select id='95A327F2C2'><dt id='95A327F2C2'><span id='95A327F2C2'></span></dt></select></label></b><u id='95A327F2C2'></u>
          <i id='95A327F2C2'><strike id='95A327F2C2'><tt id='95A327F2C2'><pre id='95A327F2C2'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:Wikipedia    Page View:9424
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In